back-office Open An Account
partner-with-us Partner with Us
Corporate Actions
Zydus Lifesciences launches PEPAIR, India's first affordable OPEP device at Rs 990

17-Feb-26   12:50 Hrs IST

The drug-free, handheld device features a patented 3-resistance system to aid mucus clearance and improve breathing in patients with COPD, asthma, and bronchiectasis.

PEPAIR is being launched in partnership with AeroDel Technology Innovations, a domestic medical device firm specializing in inhalation and pulmonary rehabilitation solutions. The device addresses chronic mucous hypersecretion, which affects over 90 lakh patients in India, by promoting airway clearance, reducing cough, and supporting optimal respiratory therapy.

Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, 'PEPAIR' introduces a patient-centric, drug-free solution to make airway clearance accessible and affordable for millions of patients with chronic respiratory conditions in India.'

Respiratory diseases in India are rising due to air pollution, urbanization, climate-driven allergens, and delayed diagnosis of chronic lung conditions. OPEP therapy, recommended in clinical guidelines, has seen limited adoption due to cost constraints'an access gap PEPAIR' aims to fill.

Zydus is a leading player in respiratory care in India, with a strong portfolio of oral bronchodilators and inhalation therapies, including Deriphyllin', Forglyn', Forglyn' Plus, Odihale'G, and Umiflo' Plus. The company continues to expand its innovation in ICS+LABA, LABA+LAMA, and single-inhaler triple therapies.

Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences shed 0.23% to Rs 907.90 on the BSE.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.